Entero Therapeutics (ENTO) Competitors $2.28 +0.13 (+6.05%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.20 -0.08 (-3.51%) As of 08/29/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ENTO vs. BFRG, GOVX, LGVN, ERNA, THAR, FLGC, IXHL, IMCC, CYCC, and PHIOShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Bullfrog AI (BFRG), GeoVax Labs (GOVX), Longeveron (LGVN), Ernexa Therapeutics (ERNA), Tharimmune (THAR), Flora Growth (FLGC), Incannex Healthcare (IXHL), IM Cannabis (IMCC), Cyclacel Pharmaceuticals (CYCC), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Its Competitors Bullfrog AI GeoVax Labs Longeveron Ernexa Therapeutics Tharimmune Flora Growth Incannex Healthcare IM Cannabis Cyclacel Pharmaceuticals Phio Pharmaceuticals Bullfrog AI (NASDAQ:BFRG) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability. Is BFRG or ENTO more profitable? Bullfrog AI's return on equity of -195.35% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bullfrog AIN/A -195.35% -162.37% Entero Therapeutics N/A -1,063.82%-17.94% Which has more risk and volatility, BFRG or ENTO? Bullfrog AI has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Do institutionals & insiders hold more shares of BFRG or ENTO? 1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 24.7% of Bullfrog AI shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, BFRG or ENTO? Bullfrog AI has higher revenue and earnings than Entero Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBullfrog AI$60K203.28-$6.99M-$0.76-1.59Entero TherapeuticsN/AN/A-$18.06MN/AN/A Does the media prefer BFRG or ENTO? In the previous week, Entero Therapeutics had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 2 mentions for Entero Therapeutics and 1 mentions for Bullfrog AI. Entero Therapeutics' average media sentiment score of 1.23 beat Bullfrog AI's score of 0.93 indicating that Entero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Bullfrog AI Positive Entero Therapeutics Positive SummaryEntero Therapeutics beats Bullfrog AI on 5 of the 9 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.63M$3.08B$5.69B$9.74BDividend YieldN/A2.28%6.64%4.48%P/E RatioN/A20.9283.1926.59Price / SalesN/A352.35515.16159.07Price / CashN/A43.5325.6628.92Price / Book-0.939.7811.766.08Net Income-$18.06M-$54.01M$3.27B$265.93M7 Day Performance11.22%0.10%1.13%0.36%1 Month Performance80.78%8.52%8.30%5.58%1 Year Performance85.32%7.03%62.26%19.67% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero TherapeuticsN/A$2.28+6.0%N/A+85.3%$3.63MN/A0.009Negative NewsGap UpBFRGBullfrog AI0.7804 of 5 stars$1.22-3.2%N/A-53.1%$12.29M$60K-1.604GOVXGeoVax Labs2.1016 of 5 stars$0.76+7.4%$8.50+1,019.9%-83.9%$12.09M$6.14M-0.3810Positive NewsLGVNLongeveron3.4544 of 5 stars$0.79-4.4%$7.25+816.6%-59.4%$12.01M$2.07M-0.1320Positive NewsERNAErnexa Therapeutics0.7004 of 5 stars$1.56+0.6%N/A-95.2%$11.96M$580K-0.1910Positive NewsGap UpTHARTharimmune3.3642 of 5 stars$2.69+130.3%$17.00+531.0%+118.8%$11.91MN/A-0.422Gap UpHigh Trading VolumeFLGCFlora Growth3.2364 of 5 stars$20.44+8.9%$93.00+354.9%-48.3%$11.81M$52.37M-0.59280Positive NewsGap UpIXHLIncannex Healthcare0.1193 of 5 stars$0.40+4.9%N/A-62.6%$11.80M$10K-0.333IMCCIM Cannabis1.1185 of 5 stars$2.22-12.2%N/A-4.9%$11.69M$39.44M-4.12340Positive NewsGap DownCYCCCyclacel Pharmaceuticals1.0748 of 5 stars$7.24-3.4%N/A-96.7%$11.54M$40K-0.0114Positive NewsPHIOPhio Pharmaceuticals2.5084 of 5 stars$1.97-2.0%$14.00+610.7%-27.6%$11.29MN/A-0.6110 Related Companies and Tools Related Companies Bullfrog AI Competitors GeoVax Labs Competitors Longeveron Competitors Ernexa Therapeutics Competitors Tharimmune Competitors Flora Growth Competitors Incannex Healthcare Competitors IM Cannabis Competitors Cyclacel Pharmaceuticals Competitors Phio Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTO) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
